Verify the current MUE table for CPT 96372 against the April 2026 release before billing multiple units on the same date of service Source: CMS MUE Table GLP-1 Coverage Expansion: Medicare Part B coverage for GLP-1 agents used for obesity management is expanding in 2026
Dipeptidyl peptidase-4 inhibition prevents vascular aging in mice under chronic stress: modulation of oxidative stress and inflammation
Intravenous thrombolysis was administered to 33.3% of patients
Meitheal Pharmaceuticals (Meitheal) is pleased to announce the official launch of two new strengths of Cyanocobalamin Injection, USP: 71288-301-11: Cyanocobalamin Injection, USP 10,000 mcg per 10 mL MDV 71288-302-30: Cyanocobalamin Injection, USP 30,000 mcg per 30 mL MDV ABOUT CYANOCOBALAMIN INJECTION, USP Cyanocobalamin is indicated for vitamin B 12 deficiencies due to malabsorption which may be associated with the following conditions: Addisonian (pernicious anemia) Gastrointestinal pathology, dysfunction, or surgery, including gluten enteropathy or sprue, small bowel bacteria overgrowth, total or partial gastrectomy Fish tapeworm infestation Malignancy of pancreas or bowel Folic acid deficiency It may be possible to treat the underlying disease by surgical correction of anatomic lesions leading to small bowel bacterial overgrowth, expulsion of fish tapeworm, discontinuation of drugs leading to vitamin malabsorption, use of a gluten-free diet in nontropical sprue, or administration of antibiotics in tropical sprue
